Amicus (FOLD) Gets a Buy Rating from Cantor Fitzgerald


Cantor Fitzgerald analyst Elemer Piros maintained a Buy rating on Amicus (FOLD) today and set a price target of $20. The company’s shares closed on Friday at $13.06.

According to TipRanks.com, Piros ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.0% and a 41.9% success rate. Piros covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Proteostasis Therapeutics Inc, and Strongbridge Biopharma Plc.

Currently, the analyst consensus on Amicus is a Strong Buy with an average price target of $19.83, a 51.8% upside from current levels. In a report issued on February 28, Cowen & Co. also maintained a Buy rating on the stock with a $31 price target.

See today’s analyst top recommended stocks >>

Based on Amicus’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $78.08 million. In comparison, last year the company had a GAAP net loss of $69.21 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts